Screening Recommendations for an 81‑Year‑Old Woman

Breast Cancer Screening

The American Cancer Society (ACS) 2015 guideline gives a qualified recommendation for biennial mammography in women ≥ 55 years who are in reasonably good health with an estimated life expectancy of ≥ 10 years; annual screening may be continued based on patient preference. 1
The American College of Physicians (ACP) advises continuing screening mammography at least until age 75 years; for ages > 75 years, decisions should be based on overall health status and projected longevity rather than chronological age alone. 2
Clinical breast examination is not recommended as a breast‑cancer screening tool for average‑risk women at any age. 1
At age 81, mammography should be offered only if the individual is in good health with an expected remaining lifespan of ≥ 10 years; otherwise the potential harms (false‑positive results, unnecessary procedures) may outweigh benefits. 2

The U.S. Preventive Services Task Force (USPSTF) recommends routine colorectal‑cancer screening through age 75 years; for ages 76‑85 years, screening decisions should be individualized according to health status, prior screening history, and patient preferences. 3
USPSTF‑approved screening modalities include:
- Annual fecal immunochemical test (FIT)
- Multitarget stool DNA‑FIT every 1–3 years
- Colonoscopy every 10 years
- CT colonography every 5 years
- Flexible sigmoidoscopy every 5 years
For adults ≥ 86 years, routine colorectal‑cancer screening is generally not recommended because competing mortality risks outweigh any survival benefit. 3
At age 81, if the patient has never been screened or is not up‑to‑date, screening should be offered provided she is in good health. 3
If the patient has had adequate prior screening (e.g., a normal colonoscopy within the past 10 years), additional screening is not required. 3

The ACS guideline (2019) states that cervical‑cancer screening should be discontinued in women > 65 years who have had adequate prior screening with consistently normal results. 4
Adequate prior screening is defined as either:
- ≥ 3 consecutive negative Pap tests, or
- ≥ 2 consecutive negative HPV + Pap co‑tests within the preceding 10 years, with the most recent test performed within the last 5 years. 4
Women who have undergone a total hysterectomy with removal of the cervix should also stop cervical screening unless the surgery was performed for cervical cancer or its precursors. 5

The USPSTF gives a B recommendation (moderate certainty of moderate net benefit) for osteoporosis screening in all women ≥ 65 years. 6
Screening is performed with dual‑energy X‑ray absorptiometry (DEXA) of the hip and lumbar spine. 6
Osteoporosis is defined as a bone‑mineral‑density T‑score ≤ ‑2.5 at the hip or lumbar spine. 6

Do not continue cervical‑cancer screening in women > 65 years with adequate prior negative results, as this constitutes overscreening with potential harms. 4
Do not perform clinical breast examination as a screening tool for average‑risk women; it adds no benefit beyond mammography. 1
Do not automatically continue all cancer screenings without evaluating life expectancy and health status; screening benefits generally require an expected remaining lifespan of at least 5–10 years to outweigh harms. 2
Do not overlook osteoporosis screening in women ≥ 65 years, given its high‑yield impact on fracture prevention. 6

Women aged ≥ 55 years should transition to biennial mammography, with the option to continue annual screening based on patient preference and overall health status. 7
Mammography should be continued as long as the individual is in good health and has an estimated life expectancy of at least 10 years. 8
At age 75, the decision to screen with mammography should be guided by overall health and projected longevity rather than chronological age alone. 8
Clinical breast examination is not recommended as a routine screening tool for average‑risk adults at any age. 7
Breast self‑examination is also not recommended because it does not improve outcomes and increases false‑positive evaluations. 8

Adults in good health with a life expectancy > 10 years should continue colorectal cancer screening up to age 75. 9
For ages 76–85, screening decisions should be individualized according to health status, prior screening history, and patient preferences. 9
Acceptable screening modalities (all supported by guideline societies) include:
- Fecal immunochemical test (FIT) annually;
- High‑sensitivity guaiac‑based fecal occult blood test annually;
- Multitarget stool DNA test every 3 years;
- Colonoscopy every 10 years;
- CT colonography every 5 years;
- Flexible sigmoidoscopy every 5 years. 7
The average time required to prevent one colorectal‑cancer death is ≈ 10.3 years; therefore, screening benefits are realized only when the individual has an adequate remaining lifespan. 9

Women aged > 65 years who have had adequate prior screening (≥ 3 consecutive negative cytology tests or ≥ 2 consecutive negative HPV‑plus‑cytology co‑tests within the past 10 years, with the most recent test ≤ 5 years ago) should stop routine cervical cancer screening. 7
Women who have undergone a total hysterectomy with removal of the cervix may also discontinue cervical screening unless the surgery was performed for cervical cancer or its precursors. 10

Low‑dose computed tomography (LDCT) screening is recommended for current or former smokers aged 55–74 years with a ≥ 30 pack‑year smoking history who currently smoke or quit ≤ 15 years ago. 7
Individuals aged ≥ 75 years do not qualify for routine LDCT lung‑cancer screening based on age alone, even if smoking criteria are met. 10

Cancer screening should not be continued automatically without assessing life expectancy; most screening benefits require an expected remaining lifespan of at least 5–10 years. 9
Routine endometrial cancer screening is not recommended; clinicians should counsel patients to report any unexpected vaginal bleeding or spotting. 10